3 14

Cited 0 times in

Cited 0 times in

A Multi-Center, Prospective, Observational Study to Evaluate the Therapeutic Effectiveness and Safety of an Olmesartan/Amlodipine Plus Rosuvastatin Combination Treatment in Patients with Concomitant Hypertension and Dyslipidemia

Authors
 Lee, Bong-Ki  ;  Kim, Byeong-Keuk  ;  Park, Jae Hyoung  ;  Chung, Jong-Won  ;  Park, Chang Gyu  ;  Kim, Jin Won  ;  Kim, Young Dae  ;  Park, Woo-Jung  ;  Kim, Sang-Hyun  ;  Cha, Jae-Kwan  ;  Kim, Cheol Ho  ;  Rha, Seung-Woon  ;  Hong, Young Joon  ;  Shin, Mi-Seung  ;  Cho, Seong Wook  ;  Sung, Young-Hee  ;  Lee, Kiheon  ;  Yu, Jae-Myung  ;  Ryu, Dong-Ryeol  ;  Yu, Sungwook  ;  Song, Tae-Jin  ;  Ku, Bon D.  ;  Kim, Sin-Gon  ;  Park, Hwan-Cheol  ;  Cho, Deok-Kyu  ;  Kim, Byung-Su  ;  Han, Seong-Woo  ;  Park, Sung-Ji  ;  Park, Gyung-Min  ;  Han, Kyoo-Rok 
Citation
 JOURNAL OF CLINICAL MEDICINE, Vol.14(2), 2025-01 
Article Number
 308 
Journal Title
JOURNAL OF CLINICAL MEDICINE
ISSN
 2077-0383 
Issue Date
2025-01
Keywords
hypertension ; dyslipidemia ; blood pressure ; low-density lipoprotein cholesterol ; observational study ; single-pill combination
Abstract
Introduction: This study assessed the therapeutic effectiveness of a single-pill combination (SPC) of olmesartan/amlodipine plus rosuvastatin for blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) in patients with hypertension and dyslipidemia. Methods: Adult patients with hypertension and dyslipidemia who were decided to be treated with the study drug were eligible. The primary endpoint was the proportion of patients who achieved BP, LDL-C and both BP and LDL-C treatment goals at weeks 24-48. Secondary endpoints were assessed at weeks 24-48 and included changes in BP and LDL-C levels from baseline; the proportion of patients who achieved treatment goals who were initially classified as uncontrolled at baseline; changes and percent changes in lipid parameters; changes in both BP and LDL-C levels among patients who reached treatment goals who were followed for more than 24 weeks; and the overall safety profile. Results: A total of 5476 patients were enrolled, and 4411 patients comprised the effectiveness evaluation set. The proportions of patients who reached the treatment goals for BP, LDL-C levels, and both BP and LDL-C levels were 67.93% [95% confidence interval (CI) 66.52-69.32], 80.19% [95% CI 78.85-81.49], and 58.07% [95% CI 56.43-59.7], respectively. Secondary endpoints showed statistically significant changes. Overall, the treatment was well tolerated. Conclusions: The treatment of patients with hypertension and dyslipidemia with the olmesartan/amlodipine plus rosuvastatin SPC was associated with significant decreases in SBP/DBP and LDL-C levels, and a high proportion of patients achieved the BP and LDL-C treatment goals. The finding of this study is worthwhile in that this study evaluated the effectiveness and safety in a broad patient population representative of those seen in everyday clinical practice.
Files in This Item:
87952.pdf Download
DOI
10.3390/jcm14020308
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Byeong Keuk(김병극) ORCID logo https://orcid.org/0000-0003-2493-066X
Cho, Deok Kyu(조덕규)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/208733
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links